Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Liabilities and Shareholders Equity (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $79.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 43.14% to $79.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $406.4 million, a 37.11% decrease, with the full-year FY2024 number at $126.9 million, down 27.4% from a year prior.
  • Liabilities and Shareholders Equity was $79.6 million for Q3 2025 at Werewolf Therapeutics, down from $92.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $195.1 million in Q1 2023 to a low of $79.6 million in Q3 2025.
  • A 5-year average of $153.6 million and a median of $172.4 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 84.08% in 2022, then plummeted 43.14% in 2025.
  • Werewolf Therapeutics' Liabilities and Shareholders Equity stood at $179.2 million in 2021, then fell by 10.6% to $160.2 million in 2022, then increased by 9.1% to $174.8 million in 2023, then decreased by 27.4% to $126.9 million in 2024, then crashed by 37.27% to $79.6 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Liabilities and Shareholders Equity are $79.6 million (Q3 2025), $92.6 million (Q2 2025), and $107.2 million (Q1 2025).